Acutaas Chemicals Ltd. share price target

Strategic Expansion: Battery & semiconductor chemical segments

Acutas Chemicals delivered robust revenue and profit growth, driven by strong performance in API and specialty chemicals segment.

Acutaas Chemicals registered a superlative performance in Q2FY26. Revenue, EBITDA and PAT registered strong growth of 24%,95% and 94% respectively on YoY terms. We believe the company will can clock in revenue CAGR of 25-30% for the next 2 years with margins upwards of 29%. The growth will be propelled by strong growth in the advanced pharma intermediates business owing to strong traction in CDMO business and targeting of more molecules which will go off patent. We believe that strong traction in key molecules will continue along with further scale up of CDMO business with the increasing ramp up of the...

Acutaas Chemicals registered a strong performance in Q1FY26. Revenue, EBITDA and PAT registered strong growth of 17%,73% and 218% respectively on YoY terms albeit from a weak base. We believe the company will can clock in revenue CAGR of 25-30% for the next 2 years with margins upwards of 23%. The growth will be propelled by strong growth in the advanced pharma intermediates business owing to strong traction in CDMO business and targeting of more molecules which will go off patent. We believe that strong traction in key molecules will continue along with further scale up of CDMO business with...

Acutaas Chemicals Limited (formerly known as Ami Organics Limited) has announced a strategic investment of up to INR 2 Bn in its wholly owned subsidiary, Acutaas Advance Material Limited (AAML), to support expansion in the semiconductor chemicals business.

AMIORG: Emerging pharma intermediate play; riding on Chinese import substitution. Technology & Internet: Significant jump in FY22 growth guidance

Company benefits from the best of two domains in chemical industry: Pharma intermediates and specialty chemicals

...

IPO NOTE

10 each, (Comprising of fresh issue of 3,278,689 Equity Shares* (Rs. 200 cr.) and Offer for Sale of 6,059,600 Equity Shares (Rs. 369.6 cr.*) by Selling Shareholder)....

Ami Organics Limited IPO Note Issue Open: Sep 01 Sep 03 2021 Price Band: Rs. 603 610 *Issue Size: 9,338,289 eq shares (Fresh Issue of Rs.200 cr + Offer for sale of 6,059,600 eq sh ) Issue Size: Rs.563.1 569.6 cr Reservation for: QIB Upto 50% eq sh Non Institutional atleast 15% eq sh Retail atleast 35% eq sh

Ami organics was incorporated in 2004, Company is one of the leading Research & Development driven company. Ami organics deal in different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) and materials for agrochemical and fine chemicals. Ami Organics has 3 manufacturing facilities situated in Gujarat with an aggregate installed capacity of 6060

Incorporated in 2004, Ami Organics is a research and development (R&D;) driven manufacturer of specialty chemicals with varied end usage, focused on the development and manufacture of advanced pharmaceutical intermediates (pharma intermediates) for regulated and generic active pharmaceutical ingredients (APIs) and new chemical entities (NCE) and key starting material for agrochemical and fine chemicals, especially from recent acquisition of the business of Gujarat Organics Ltd. It is one of the major manufacturers of pharma intermediates for certain key APIs, including...